............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Oxford Immunotec announces contract with
Scancell Ltd to measure T cell
Oxford, UK and Marlborough, MA; 23rd March 2010 – Oxford
Immunotec Ltd, the T cell measurement company, today announces
that it has signed a contract with Scancell Ltd to provide
services in support of Scancell’s Phase I/II clinical trial with
SCIB1 Scancell’s DNA ImmunoBody® vaccine for the treatment of
melanoma. Under the contract, Oxford Immunotec will utilize its
ELISpot technology to measure T cell responses to SCIB1.
Scancell’s immunotherapy is designed to generate the
high-avidity T-cells that kill cancer cells. Oxford Immunotec’s
laboratory will provide T cell separation, cryo-preservation and
the ELISpot assays required by Scancell to measure T cell
responses to SCIB1.
Commenting on the collaboration, Dr Peter Wrighton-Smith, Chief
Executive Officer of Oxford Immunotec, said, "As our
understanding of human immune biology progresses, we expect to
see an increasing number of innovative approaches that elicit
response from the cellular components of the immune systems, in
particular T cell responses. Monitoring of T cell responses in
trials such as Scancell’s melanoma immunotherapy trial will
become increasingly important in correlating therapeutic effects
of new products on the immune system and clinical end points."
Professor Lindy Durrant, Chief Executive Officer of Scancell
Ltd., stated, "We were impressed with Oxford Immunotec’s ELISpot
expertise and systems and are delighted to use the company’s
services for this critical assay in the assessment of safety and
efficacy of our lead ImmunoBody® vaccine, SCIB1". |